Abstract 1158P
Background
There is no generally accepted model to predict overall survival (OS) of patients treated with peptide receptor radionuclide therapy (PRRT) for small intestinal neuroendocrine tumors (siNET).
Methods
We searched literature for non-experimental clinical and biochemical predictors of OS after treatment with PRRT. Among 13 potential markers related to patient baseline status, function of organs affected by PRRT toxicity, inflammation, tumor burden and tumor proliferation, seven candidate variables were selected based on previous publication results, and analyzed in a retrospective cohort of 326 patients treated with PRRT between 2005 and 2019 in a tertiary referral center. An accelerated failure-time model was used and a nomogram was constructed. The model was internally validated with bootstrapping, and its discrimination and calibration evaluated with Harrell’s c-index and calibration plots.
Results
During a median follow-up of 40 months, there were 230 deaths. All selected variables were significantly associated with OS in unadjusted analysis. A prognostic nomogram was created using age (0-68) and performance status (PS, 0-44), tumor markers chromogranin A (CgA, log, 0-100) and 5-hydroxyindoloacetaic acid (5HIAA, 0-57), albumin (0-15), alkaline phosphatase (ALP, log, 0-20) and hemoglobin (Hb, 0-32). The full model had good discriminatory ability (optimism-corrected c-index 0.74) and calibration. A backward selection algorithm was used to approximate the full model. The final model contained age, PS, CgA, 5HIAA and Hb.
Conclusions
We suggest a novel nomogram, based on a small number of readily available clinical and biochemical parameters, to predict OS after treatment with PRRT for siNET. Our nomogram may assist clinicians in more accurate clinical decision-making and patient counseling.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Swedish Cancer Society, Futurum – the Academy for Health and Care, Region Jönköping County.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
498P - Report of 9 cases of embryonal tumours of the central nervous system with multilayered rosettes (ETMR)
Presenter: Ruyu Ai
Session: Poster session 17
Resources:
Abstract
499TiP - A phase II study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy
Presenter: Brian Stockdale
Session: Poster session 17
500TiP - Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Presenter: Michael Weller
Session: Poster session 17
501TiP - Clinical performance evaluation of a brain cancer liquid biopsy
Presenter: James Cameron
Session: Poster session 17
692P - Role of adjunctive surgery after platinum-based chemotherapy in management patients with adrenocortical carcinoma: Observation study
Presenter: Yaroslav Zhulikov
Session: Poster session 17
693P - Causes of death in patients with malignant adrenal tumors: A population-based analysis
Presenter: Shangqing Ren
Session: Poster session 17
946P - Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior atezolizumab and bevacizumab treatment: A multicenter retrospective study
Presenter: Jung Sun Kim
Session: Poster session 17
948P - Drug type and duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma with high-risk recurrence factors (PREVENT): An update analysis of a prospective, multicentric cohort study
Presenter: Jia-Yong Su
Session: Poster session 17
Resources:
Abstract
949P - Update results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection
Presenter: Xianhai Mao
Session: Poster session 17
950P - Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
Presenter: Masatoshi Kudo
Session: Poster session 17